Danaher Co. (NYSE:DHR) Stock Holdings Lessened by Evoke Wealth LLC

Evoke Wealth LLC lowered its stake in Danaher Co. (NYSE:DHR) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,147 shares of the conglomerate’s stock after selling 70 shares during the period. Evoke Wealth LLC’s holdings in Danaher were worth $1,872,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of DHR. FMR LLC increased its holdings in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after buying an additional 3,217,631 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Danaher in the fourth quarter valued at $391,172,000. Van ECK Associates Corp increased its holdings in shares of Danaher by 6,862.7% in the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after buying an additional 916,513 shares in the last quarter. Parnassus Investments LLC increased its holdings in shares of Danaher by 31.8% in the fourth quarter. Parnassus Investments LLC now owns 3,105,388 shares of the conglomerate’s stock valued at $712,842,000 after buying an additional 749,136 shares in the last quarter. Finally, Proficio Capital Partners LLC raised its stake in Danaher by 29,287.7% during the 4th quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock valued at $135,189,000 after purchasing an additional 586,925 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.1 %

Shares of NYSE:DHR opened at $212.71 on Wednesday. The stock has a market capitalization of $152.03 billion, a PE ratio of 40.29, a P/E/G ratio of 2.66 and a beta of 0.82. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The firm has a fifty day moving average price of $219.04 and a 200 day moving average price of $239.67. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the firm earned $2.09 earnings per share. Analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.60%. This is a boost from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. Danaher’s dividend payout ratio is 24.24%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.90% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on DHR shares. Robert W. Baird cut their target price on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Guggenheim started coverage on shares of Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $277.00 target price (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Stifel Nicolaus raised shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 target price on the stock in a research note on Friday, March 14th. Finally, Scotiabank initiated coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Six analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $277.76.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.